Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 06.10.2025 1 Acta Haematol 3 Am J Hematol 4 Ann Hematol 4 Blood 1 BMC Cancer 1 Br J Cancer 1 Cancer Chemother Pharmacol 3 Cancer Lett 1 Cancer Res 2 Int J Hematol 2 Leuk Res 8 Leukemia 1 Oncol Rep 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. MIN KI, Kwag D, Min GJ, Park SS, et al
   Ponatinib Monotherapy in adult patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including MRD Relapse.
   Acta Haematol. 2025 Oct 2:1-22. doi: 10.1159/000548544.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. SOCKEL K, Rollig C, Mutherig A, Crysandt M, et al
   Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
   Am J Hematol. 2025 Oct 2. doi: 10.1002/ajh.70091.
   PubMed         Abstract available
   
   
3. VALTIS YK, Nemirovsky D, Derkach A, Cacace I, et al
   Venetoclax in Combination With Pediatric-Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial.
   Am J Hematol. 2025 Sep 27. doi: 10.1002/ajh.70082.
   PubMed        
   
   
4. FATHIMA S, Alsugair A, Yousuf M, Faldu P, et al
   Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.
   Am J Hematol. 2025 Sep 25. doi: 10.1002/ajh.70080.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. YANG Y, Zhang X, Jiang N, Jin Y, et al
   Correction to: Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
   Ann Hematol. 2025 Oct 1. doi: 10.1007/s00277-025-06665.
   PubMed        
   
   
6. DAI Y, Ai Y, Sun S, Tang M, et al
   Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature.
   Ann Hematol. 2025 Sep 29. doi: 10.1007/s00277-025-06596.
   PubMed         Abstract available
   
   
7. LI ST, Shi XM, Liu QJ, Tan YH, et al
   Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.
   Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06618.
   PubMed         Abstract available
   
   
8. CHEN H, Chen M, Yang Z, Liao S, et al
   Identification of a novel PML exon 6 splice variant in atypical PML::RARalpha transcripts in acute promyelocytic leukemia.
   Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06613.
   PubMed         Abstract available
   
   

   
   Blood

9. PENTER L, Maurer K, Cieri N, Lu W, et al
   Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
   Blood. 2025 Sep 30:blood.2025029121. doi: 10.1182/blood.2025029121.
   PubMed         Abstract available
   
   
10. DEREVYANKO PK, Swart LE, Mata Casimiro LD, van Oort A, et al
    Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia.
    Blood. 2025 Sep 24:blood.2025028988. doi: 10.1182/blood.2025028988.
    PubMed         Abstract available
    
    
11. NEDUMANNIL R, Ashby M, Rowland J, Malherbe JAJ, et al
    Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.
    Blood. 2025;146:1625-1629.
    PubMed         Abstract available
    
    
12. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
    Blood. 2025;146:1664-1676.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. XIONG Y, Chen Y, Luo H, Shi M, et al
    DHX9 as a prognostic biomarker and its biological roles in acute myeloid leukemia.
    BMC Cancer. 2025;25:1464.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. GIL JV, Avetisyan G, Miralles A, de Las Heras S, et al
    Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia.
    Br J Cancer. 2025 Sep 30. doi: 10.1038/s41416-025-03204.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

15. COHEN IJ
    Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship.
    Cancer Chemother Pharmacol. 2025;95:95.
    PubMed        
    
    

    
    Cancer Lett

16. MA W, Jamieson C
    Developmental checkpoint targeting: Pre-TCR immunotherapy in leukemia and beyond.
    Cancer Lett. 2025 Sep 26:218063. doi: 10.1016/j.canlet.2025.218063.
    PubMed        
    
    
17. MILLS TS, Arnone M, Gorsch E, Poeschel S, et al
    MRC2 expression modulates metabolism in acute myeloid leukemia stem cells.
    Cancer Lett. 2025 Sep 26:218068. doi: 10.1016/j.canlet.2025.218068.
    PubMed         Abstract available
    
    
18. HE SJ, Shu LP, Zhou ZW, Yang T, et al
    Corrigendum to "Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells" [Cancer. Lett. (382) 2016-11-28; 382(2):215-230].
    Cancer Lett. 2025 Sep 27:218039. doi: 10.1016/j.canlet.2025.218039.
    PubMed        
    
    

    
    Cancer Res

19. ZWICK M, Zinkel B, Spohr C, Ruckert T, et al
    FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.
    Cancer Res. 2025 Oct 3. doi: 10.1158/0008-5472.CAN-25-0349.
    PubMed         Abstract available
    
    

    
    Int J Hematol

20. AKAHANE K, Kasai S, Tamai M, Sugita Y, et al
    Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.
    Int J Hematol. 2025;122:611-615.
    PubMed         Abstract available
    
    
21. IMI T, Asakura H, Sato K, Yamada S, et al
    Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
    Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020.
    PubMed         Abstract available
    
    

    
    Leuk Res

22. SHANG J, Chen WM, Liu S, Wang ZH, et al
    Corrigendum to "CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy" [Leuk. Res., 85 (2019) 106198].
    Leuk Res. 2025 Sep 23:108111. doi: 10.1016/j.leukres.2025.108111.
    PubMed        
    
    
23. FUJIOKA M, Mishima H, Itonaga H, Hamaguchi Y, et al
    Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1.
    Leuk Res. 2025;158:108112.
    PubMed         Abstract available
    
    

    
    Leukemia

24. SMITH C, Charbonnier G, Simonin M, Balducci E, et al
    Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).
    Leukemia. 2025;39:2344-2354.
    PubMed         Abstract available
    
    
25. KAPAHNKE K, Plenge T, Klaus T, Gupta MK, et al
    The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.
    Leukemia. 2025;39:2406-2418.
    PubMed         Abstract available
    
    
26. PEREZ-AMILL L, Armand-Ugon M, Val-Casals M, Martin-Herreros B, et al
    A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
    Leukemia. 2025;39:2432-2441.
    PubMed         Abstract available
    
    
27. MOINARD S, Lebecque B, Lachaise T, Johnson-Ansah H, et al
    Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
    Leukemia. 2025;39:2375-2383.
    PubMed         Abstract available
    
    
28. TIRTAKUSUMA R, Ghonim MA, Schattgen S, Muller B, et al
    Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.
    Leukemia. 2025;39:2419-2431.
    PubMed         Abstract available
    
    
29. ZHANG X, Li M, Chen Y, Liu J, et al
    Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression.
    Leukemia. 2025;39:2355-2363.
    PubMed         Abstract available
    
    
30. SETIAWAN T, Muhammad JA, Marcellina N, Wirawan LM, et al
    Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
    Leukemia. 2025 Oct 1. doi: 10.1038/s41375-025-02768.
    PubMed         Abstract available
    
    
31. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Oct 2. doi: 10.1038/s41375-025-02778.
    PubMed        
    
    

    
    Oncol Rep

32. ZHOU X, Li A, Kong D, Shi Y, et al
    The silent players: Atypical BCR?ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).
    Oncol Rep. 2025;54:162.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

33. TAN M, Sun S, Liu Y, Perreault AA, et al
    Targeting the 3D genome by anthracyclines for chemotherapeutic effects.
    Proc Natl Acad Sci U S A. 2025;122:e2500704122.
    PubMed         Abstract available
    
    
34. HATTORI T, Wang M, Corrado AD, Gross S, et al
    Engineering antibody-drug conjugates targeting an adhesion GPCR, CD97.
    Proc Natl Acad Sci U S A. 2025;122:e2516627122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.